Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's:COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

Neuroblastoma is one of the most common solid tumors of childhood, and patients have very low survival if it recurs after initial treatment. Natural killer (NK) cells are white blood cells that are part of your body's natural defense against cancer, and these cells are particularly good at killing neuroblastoma when they work together with immune stimulators and anti-cancer antibodies. This team has developed a new way to grow large numbers of very active NK cells. The project is testing whether NK cells in combination with the anti-neuroblastoma antibody, ch14.18, and the immune activator, lenalidomide, will improve survival for children with neuroblastoma. Awarded at University of Texas M.D. Anderson Cancer Center and transferred to The Research Institute at Nationwide Children's. Funds administered by The Research Institute at Nationwide Children's Hospital.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Multimodal immunotherapy for neuroblastoma Consortium. For a description of this project, see the consortium grant made to the lead institution: The Research Institute at Nationwide Children's Hospital, Columbus, OH.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners. Pediatric brain tumors are the leading cause of cancer-related deaths in children, and atypical teratoid/rhabdoid tumors (ATRT) are among the most aggressive, with a dismal prognosis. Moreover, treatment related toxicities of current standard therapies cause long term health issues. Researchers at Stanford University, as part of the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team, recently discovered that 100% of ATRT tumors express a protein called B7-H3 and demonstrated that this can be a novel target for cancer immunotherapy. Chimeric Antigen Receptor (CAR) T cells targeting B7-H3 demonstrated dramatic responses against preclinical models of ATRT. They further demonstrated that CAR T cells administered into the central nervous system were more potent and less toxic than systemically administered CAR T cells. This therapy has the potential to dramatically alter outcome for children with these aggressive cancers, and researchers are working towards translating the recent findings into the clinic. A portion of this project is generously supported by Hope4ATRT, a St. Baldrick's charity partner. Zion Yamoah was diagnosed with an aggressive brain tumor called AT/RT just before his third birthday and passed away 15 months later. His love of music and his bright spirit inspired his parents to establish Hope4ATRT. Its mission is to raise funds for innovative research specifically targeted for AT/RT while also helping families to navigate available treatment options and current research in the field. A portion of this project is generously supported by Bianka's Butterfly Fund for PNET Brain Tumor Research, a St. Baldrick's Hero Fund. Four-year old Bianka Kucelin was diagnosed with a malignant brain cancer known as PNET. Despite extensive treatment, the little girl who loved butterflies passed away in May 2015. Bianka will be remembered for her joyful spirit and courageous grace. This Hero Fund honors her life and aspires to fund PNET research grants.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.